US2002015703A1PendingUtilityA1

Antagonists of tweak and of tweak receptor and their use to treat immunological disorders

52
Priority: Jan 15, 1999Filed: Jul 13, 2001Published: Feb 7, 2002
Est. expiryJan 15, 2019(expired)· nominal 20-yr term from priority
Inventors:Paul Rennert
A61P 43/00A61P 7/06A61P 37/00A61P 37/08A61P 7/00A61P 37/02A61P 37/06A61P 35/00A61P 35/02A61P 29/00A61P 31/00A61P 31/18A61P 13/12A61P 21/00A61P 21/04C07K 2319/30C07K 16/2875C07K 14/70575A61K 2039/505C07K 16/2878A61K 39/395
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for blocking the development or treating or reducing the severity or effects of an immunological disorder in an animal comprising the step of administering a pharmaceutical composition which comprises a therapeutically effective amount of a TWEAK blocking agent and a pharmaceutically acceptable carrier.  
     
     
         2 . A method for inhibiting an immune response in an animal comprising the step of administering a pharmaceutical composition which comprises an effective amount of a TWEAK blocking agent and a pharmaceutically effective carrier.  
     
     
         3 . The method according to  claim 1  or  2 , wherein the TWEAK blocking agent is selected from the group consisting of: 
 (a) an antibody directed against the TWEAK ligand;  
 (b) an antibody directed against the TWEAK receptor;  
 (c) an agent that modifies the binding of the TWEAK ligand to the receptor;  
 (d) an agent that modifies the cell surface receptor clustering; and  
 (e) an agent that can interrupt the intra cellular signaling of the TWEAK receptor.  
 
     
     
         4 . The method according to  claim 1  or  2 , wherein the animal is mammalian.  
     
     
         5 . The method according to  claim 4 , wherein the mammal is human.  
     
     
         6 . The method according to  claim 1  or  2 , wherein the TWEAK blocking agent comprises a soluble TWEAK receptor having a ligand binding domain that can selectively bind to a surface TWEAK ligand.  
     
     
         7 . The method of  claim 6 , wherein the soluble TWEAK receptor comprises a human immunoglobulin IgG domain.  
     
     
         8 . The method of  claim 7 , wherein the human immunoglobulin IgG domain comprises regions responsible for specific antigen binding.  
     
     
         9 . The method according to  claim 1  or  2 , wherein the antibody directed against the TWEAK receptor comprises a monoclonal antibody.  
     
     
         10 . The method according to  claim 1  or  2 , wherein the TWEAK blocking agent comprises a monoclonal antibody directed against the TWEAK surface ligand.  
     
     
         11 . The method according to  claim 10 , wherein the antibody is directed against a subunit of the TWEAK ligand.  
     
     
         12 . The method according to  claim 2 , wherein the immune response is a Th1 cell-mediated immune response.  
     
     
         13 . The method according to  claim 2 , wherein the immune response is a Th2 cell-mediated immune response.  
     
     
         14 . The method according to  claim 2 , wherein the immune response includes both a Th1 and a Th2 cell-mediated immune response.  
     
     
         15 . The method according to  claim 2 , wherein the TWEAK blocking agent comprises a monoclonal antibody directed against the TWEAK receptor.  
     
     
         16 . A pharmaceutical composition comprising a therapeutically effective amount of a TWEAK blocking agent and a pharmaceutically acceptable carrier.  
     
     
         17 . The composition according to  claim 16 , wherein the TWEAK blocking agent is selected from the group consisting of: 
 (a) an antibody directed against the TWEAK ligand;    (b) an antibody directed against the TWEAK receptor;    (c) an agent that modifies the binding of the TWEAK ligand to the receptor;    (d) an agent that modifies the cell surface receptor clustering; and    (e) an agent that can interrupt the intracellular signaling of the TWEAK receptor    
     
     
         18 . The composition according to  claim 16 , wherein the TWEAK blocking agent comprises a soluble TWEAK receptor having a ligand binding domain that can selectively bind to a surface TWEAK ligand.  
     
     
         19 . The composition according to  claim 18 , wherein the soluble TWEAK receptor comprises a human immunoglobulin IgG domain into which regions responsible for specific antigen binding have been inserted.  
     
     
         20 . The composition of  claim 16 , wherein the TWEAK blocking agent comprises a monoclonal antibody directed against the TWEAK receptor.  
     
     
         21 . The composition according to  claim 16 , wherein the TWEAK blocking agent comprises a monoclonal antibody directed against the TWEAK surface ligand.  
     
     
         22 . The composition according to  claim 21 , wherein the antibody is directed against a subunit of the TWEAK ligand.

Join the waitlist — get patent alerts

Track US2002015703A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.